As of 3:59pm ET
| -0.05 / -0.92%|
The 2 analysts offering 12-month price forecasts for Caladrius Biosciences Inc have a median target of 14.00, with a high estimate of 20.00 and a low estimate of 8.00. The median estimate represents a +160.71% increase from the last price of 5.37.
The current consensus among 3 polled investment analysts is to Buy stock in Caladrius Biosciences Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.